224 related articles for article (PubMed ID: 24191907)
21. Phase 2 clinical trial of a recombinant adeno-associated viral vector expressing α1-antitrypsin: interim results.
Flotte TR; Trapnell BC; Humphries M; Carey B; Calcedo R; Rouhani F; Campbell-Thompson M; Yachnis AT; Sandhaus RA; McElvaney NG; Mueller C; Messina LM; Wilson JM; Brantly M; Knop DR; Ye GJ; Chulay JD
Hum Gene Ther; 2011 Oct; 22(10):1239-47. PubMed ID: 21609134
[TBL] [Abstract][Full Text] [Related]
22. Phase I trial of intramuscular injection of a recombinant adeno-associated virus serotype 2 alphal-antitrypsin (AAT) vector in AAT-deficient adults.
Brantly ML; Spencer LT; Humphries M; Conlon TJ; Spencer CT; Poirier A; Garlington W; Baker D; Song S; Berns KI; Muzyczka N; Snyder RO; Byrne BJ; Flotte TR
Hum Gene Ther; 2006 Dec; 17(12):1177-86. PubMed ID: 17115945
[TBL] [Abstract][Full Text] [Related]
23. A review of α1-antitrypsin deficiency.
Stoller JK; Aboussouan LS
Am J Respir Crit Care Med; 2012 Feb; 185(3):246-59. PubMed ID: 21960536
[TBL] [Abstract][Full Text] [Related]
24. Lack of effect of oral 4-phenylbutyrate on serum alpha-1-antitrypsin in patients with alpha-1-antitrypsin deficiency: a preliminary study.
Teckman JH
J Pediatr Gastroenterol Nutr; 2004 Jul; 39(1):34-7. PubMed ID: 15187777
[TBL] [Abstract][Full Text] [Related]
25. Preclinical characterization of a recombinant adeno-associated virus type 1-pseudotyped vector demonstrates dose-dependent injection site inflammation and dissemination of vector genomes to distant sites.
Flotte TR; Conlon TJ; Poirier A; Campbell-Thompson M; Byrne BJ
Hum Gene Ther; 2007 Mar; 18(3):245-56. PubMed ID: 17376008
[TBL] [Abstract][Full Text] [Related]
26. Current status of gene therapy for α-1 antitrypsin deficiency.
Loring HS; Flotte TR
Expert Opin Biol Ther; 2015 Mar; 15(3):329-36. PubMed ID: 25363251
[TBL] [Abstract][Full Text] [Related]
27. Intracerebral Gene Therapy Using AAVrh.10-hARSA Recombinant Vector to Treat Patients with Early-Onset Forms of Metachromatic Leukodystrophy: Preclinical Feasibility and Safety Assessments in Nonhuman Primates.
Zerah M; Piguet F; Colle MA; Raoul S; Deschamps JY; Deniaud J; Gautier B; Toulgoat F; Bieche I; Laurendeau I; Sondhi D; Souweidane MM; Cartier-Lacave N; Moullier P; Crystal RG; Roujeau T; Sevin C; Aubourg P
Hum Gene Ther Clin Dev; 2015 Jun; 26(2):113-24. PubMed ID: 25758611
[TBL] [Abstract][Full Text] [Related]
28. Gene therapy progress and prospects: alpha-1 antitrypsin.
Stecenko AA; Brigham KL
Gene Ther; 2003 Jan; 10(2):95-9. PubMed ID: 12571637
[TBL] [Abstract][Full Text] [Related]
29. Histone deacetylase inhibitor (HDACi) suberoylanilide hydroxamic acid (SAHA)-mediated correction of α1-antitrypsin deficiency.
Bouchecareilh M; Hutt DM; Szajner P; Flotte TR; Balch WE
J Biol Chem; 2012 Nov; 287(45):38265-78. PubMed ID: 22995909
[TBL] [Abstract][Full Text] [Related]
30. A review of augmentation therapy for alpha-1 antitrypsin deficiency.
Mohanka M; Khemasuwan D; Stoller JK
Expert Opin Biol Ther; 2012 Jun; 12(6):685-700. PubMed ID: 22500781
[TBL] [Abstract][Full Text] [Related]
31. Gene therapy for human alpha1-antitrypsin deficiency in an animal model using SV40-derived vectors.
Duan YY; Wu J; Zhu JL; Liu SL; Ozaki I; Strayer DS; Zern MA
Gastroenterology; 2004 Oct; 127(4):1222-32. PubMed ID: 15480999
[TBL] [Abstract][Full Text] [Related]
32. Alpha-1-antitrypsin deficiency: an overview of recent advances.
El Hazmi MA
Saudi J Gastroenterol; 1996 Sep; 2(3):113-9. PubMed ID: 19864818
[TBL] [Abstract][Full Text] [Related]
33. Progress with Recombinant Adeno-Associated Virus Vectors for Gene Therapy of Alpha-1 Antitrypsin Deficiency.
Gruntman AM; Flotte TR
Hum Gene Ther Methods; 2015 Jun; 26(3):77-81. PubMed ID: 26067712
[TBL] [Abstract][Full Text] [Related]
34. Gene-based therapy for alpha-1 antitrypsin deficiency.
Mueller C; Flotte TR
COPD; 2013 Mar; 10 Suppl 1():44-9. PubMed ID: 23527792
[TBL] [Abstract][Full Text] [Related]
35. Ex vivo transduced liver progenitor cells as a platform for gene therapy in mice.
Song S; Witek RP; Lu Y; Choi YK; Zheng D; Jorgensen M; Li C; Flotte TR; Petersen BE
Hepatology; 2004 Oct; 40(4):918-24. PubMed ID: 15382177
[TBL] [Abstract][Full Text] [Related]
36. Advances in Alpha-1 Antitrypsin Gene Therapy.
Lorincz R; Curiel DT
Am J Respir Cell Mol Biol; 2020 Nov; 63(5):560-570. PubMed ID: 32668173
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of intracellular degradation increases secretion of a mutant form of alpha1-antitrypsin associated with profound deficiency.
Novoradovskaya N; Lee J; Yu ZX; Ferrans VJ; Brantly M
J Clin Invest; 1998 Jun; 101(12):2693-701. PubMed ID: 9637703
[TBL] [Abstract][Full Text] [Related]
38. Preclinical evaluation of a recombinant adeno-associated virus vector expressing human alpha-1 antitrypsin made using a recombinant herpes simplex virus production method.
Chulay JD; Ye GJ; Thomas DL; Knop DR; Benson JM; Hutt JA; Wang G; Humphries M; Flotte TR
Hum Gene Ther; 2011 Feb; 22(2):155-65. PubMed ID: 20812844
[TBL] [Abstract][Full Text] [Related]
39. The pallid mouse. A model of genetic alpha 1-antitrypsin deficiency.
Martorana PA; Brand T; Gardi C; van Even P; de Santi MM; Calzoni P; Marcolongo P; Lungarella G
Lab Invest; 1993 Feb; 68(2):233-41. PubMed ID: 8441253
[TBL] [Abstract][Full Text] [Related]
40. Pulmonary vasculature directed adenovirus increases epithelial lining fluid alpha-1 antitrypsin levels.
Buggio M; Towe C; Annan A; Kaliberov S; Lu ZH; Stephens C; Arbeit JM; Curiel DT
J Gene Med; 2016; 18(1-3):38-44. PubMed ID: 26825735
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
